News >

European Approval Sought for Luspatercept for Anemias

Gina Columbus @ginacolumbusonc
Published: Friday, Apr 26, 2019

Jay Backstrom, MD

Jay Backstrom, MD

A marketing authorization application has been submitted to the European Medicines Agency for luspatercept for the treatment of adult patients with very low- to intermediate-risk myelodysplastic syndrome (MDS)–associated anemia with ring sideroblasts who require red blood cell (RBC) transfusions and have not received or are ineligible to receive erythropoiesis-stimulating agents.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Medical Crossfire®: Personalizing Care for Multiple Myeloma Patients: Current and Future Sequencing StrategiesMay 31, 20191.5
Publication Bottom Border
Border Publication